The Biotechnology Industry in the World

The Biotechnology Industry in the World

The primary goal with the biotechnology marketplace is to invent new biologically-active substances, for that management of disease, the pharmaceutical industry, along with the control over agriculture.
The U.S. could be the world leader in biotechnology, currently providing employment for over 300,000 people in over 6,000 U.S. biotech companies, by having an estimated market capitalization of approximately USD 281 billion in 2008. The biotechnology industry has a lot more than tripled in size since 2000, with revenues increasing from USD 25 billion in 2000 to greater than USD 80 billion in 2008. In 2007, Amgen, Inc., the earth's largest biotechnology company, achieved total sales of USD 14.7 billion. Expectations are that this biotechnology market will increase to greater than USD 130 billion by 2011.

Geographically, the U.S. is the reason 65% in the biotechnology market, Europe 23%, Canada 7%, Australia 3%, and the rest from the world, 2%.
Today, genomics and bioinformatics development both of them are being pursued within major pharmaceutical companies. There have been key collaborations with traditional IT technology companies for example IBM, Hitachi, Ltd., Samsung, SK Telecomm and Motorola. The U.S. biotechnology research and pharmaceutical industry spent an increasing USD 8.5 billion in 2007 for the R&D of latest medicines and vaccines. As of 2006, the biotechnology industry compared favorably using the pharmaceutical industry with regards to R&D expenditures per employee. Venture capital investments in bioscience companies reached USD 11.6 billion in 2007.
Ernst & Young reported that in 2006, 82 publicly-traded Canadian biotech firms claimed S3.2 billion in revenue, comprising 4.4% of global biotech revenues. Human health accounts for your largest segment with the Canadian biotech industry, representing a lot more than half a persons vision coming from all biotech companies, approximately 70% of all biotech revenues and nearly 90% of biotech R&D. Bioinforrnatics provides an important capability for that Canadian biotech industry, encompassing genomics as well as other "omics", tissue engineering and drug discovery technology.
Canadian bioinformatics companies include Bioinformatics Solutions, Inc., DNA LandMarks, Inc., and Kinexus Bioinformatics Corporation. Montreal, Quebec, has Canada's leading biotech cluster, accompanied by Toronto, Ontario; Vancouver, British Columbia; and Winnipeg, Manitoba.
Five European Union (E.U.) member states-Denmark, Finland, Germany, Sweden and the U.K.-continue to get world leaders in biotech innovation along with the U.S. and Japan. In the second half' of 2007, European biotech companies reached USD 765.3 million in capital raising investment. In January and February of 2008, investment capital funds invested a complete of USD 145.6 million into new European biotech companies; however, while using economic stresses in the latter part of the year, many European biotech firms could find it harder to boost take advantage early 2009.
The Biotechnology Industry Organization of Germany (BlO Deutschland), positioned in Berlin, has over 180 members, including companies, BioRegions, and sector service providers. The goal from the organization is usually to support and promote a well balanced economy through innovation in bioscience.

Among the German biotech companies will be the Biotechnology Research and Information Network (BRAIN AG), 4SC. AG, Bionas, UmbEl and Direvo, which recently (September 2008) was purchased from the German pharmaceutical and chemicals giant Bayer HealthCare. In view of' the burgeoning German biotech sector, traditional German scientific manufacturers like Eppendorf, AG, Sartorius, AG and Qiagen also have gotten in to the act.